Say it isn’t so. Surely large corporations wouldn’t use the power of government to stifle a cheaper and more effective product. From Monica Showalter at americanthinker.com:
When President Trump brought up hydroxychloroquine as a promising potential treatment for COVID-19, a huge upsurge of negative political publicity followed from it. It was strange stuff, because up until then, the treatment, which had been safely used to treat malaria, lupus, and arthritis, had been seeing promising results for COVID-19, too. Yet the condemnations from all sides poured for weeks. It wasn’t just the political establishment blasting it; it seemed to be the medical establishment, too. That raises questions as to whether financial interests might be involved here.
It started with the press engaging in its customary contrarianism against Trump when he called the treatment “promising.” The logic was simple: If Trump liked it, then it had to be bad.
How’s this for a slanted headline and report from NPR, which ran on April 10?
COVID-19 Patients Given Unproven Drug In Texas Nursing Home In ‘Disconcerting’ Move